A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 9, 2016

Study Completion Date

November 9, 2016

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

MLN7243

"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."

Trial Locations (7)

Unknown

Boston

St Louis

Cleveland

Philadelphia

Charleston

Nashville

San Antonio

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY